- Home
- PLX vs FLL Comparison
PLX vs FLL Comparison
Compare PLX & FLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- FLL
- Stock Information
- Founded
- PLX 1993
- FLL 1987
- Country
- PLX United States
- FLL United States
- Employees
- PLX N/A
- FLL N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- FLL Hotels/Resorts
- Sector
- PLX Health Care
- FLL Consumer Discretionary
- Exchange
- PLX Nasdaq
- FLL Nasdaq
- Market Cap
- PLX 127.4M
- FLL 133.3M
- IPO Year
- PLX 1998
- FLL 1993
- Fundamental
- Price
- PLX $1.55
- FLL $3.73
- Analyst Decision
- PLX Strong Buy
- FLL Buy
- Analyst Count
- PLX 1
- FLL 5
- Target Price
- PLX $15.00
- FLL $5.80
- AVG Volume (30 Days)
- PLX 571.5K
- FLL 185.6K
- Earning Date
- PLX 08-14-2025
- FLL 08-07-2025
- Dividend Yield
- PLX N/A
- FLL N/A
- EPS Growth
- PLX N/A
- FLL N/A
- EPS
- PLX 0.08
- FLL N/A
- Revenue
- PLX $61,948,000.00
- FLL $297,653,000.00
- Revenue This Year
- PLX $14.53
- FLL $4.96
- Revenue Next Year
- PLX $75.77
- FLL $8.15
- P/E Ratio
- PLX $20.34
- FLL N/A
- Revenue Growth
- PLX 62.79
- FLL 8.24
- 52 Week Low
- PLX $0.89
- FLL $2.86
- 52 Week High
- PLX $3.10
- FLL $5.59
- Technical
- Relative Strength Index (RSI)
- PLX 47.97
- FLL 45.30
- Support Level
- PLX $1.47
- FLL $3.47
- Resistance Level
- PLX $1.57
- FLL $3.84
- Average True Range (ATR)
- PLX 0.07
- FLL 0.18
- MACD
- PLX -0.00
- FLL 0.03
- Stochastic Oscillator
- PLX 31.82
- FLL 84.30
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About FLL Full House Resorts Inc.
Full House Resorts Inc owns, operates, develops, manages, and invests in casinos and related hospitality and entertainment facilities. It offers facilities related to gaming, hotel, dining, entertainment, retail, and other amenities. The group's reportable segments are Midwest & South, West, and Contracted Sports Wagering, It generates the majority of its revenue from the Midwest & South segment which includes Silver Slipper Casino and Hotel, Rising Star Casino Resort, and American Place. The west segment includes Grand Lodge, Stockman's Casino, Bronco Billy's Casino and Hotel, and Chamonix Casino Hotel. The Contracted Sports Wagering segment comprises on-site and online sports wagering skins.